Pauling.AI, an AI-first biotech company, today announced the launch of its fully automated drug discovery agent for small molecules. The agent orchestrates end-to-end in-silico workflows, including target ingestion, molecular generation and screening, docking, molecular dynamics, and ADMET prediction, so scientists can move from hypothesis to testable candidates dramatically faster and at lower cost. Pauling.AI aims to build the best possible AI drug discovery workflow.

“AI agents should feel like a world-class computational chemist that never sleeps,” said Javier Tordable, Founder & CEO of Pauling.AI and a former Google technology leader. “By automating the heavy lifting (simulation, triage, and documentation) we let teams focus on the science that matters: choosing the right biology and advancing the best molecules.”

Early materials describe Pauling.AI as “the AI chemist that automates drug discovery,” highlighting autonomous workflows for docking and simulation, and positioning the platform to help startups go from idea to testable molecule in less than a week. The company participates in the NVIDIA Inception program and lists Google for Startups among supporters.

Agentic systems are emerging across pharma, Pauling.AI’s launch focuses currently on small-molecule programs and emphasizes turnkey automation over point tools, integrating generation, physics-based evaluation, and developability checks in one loop.

Availability

Pauling.AI’s fully automated small-molecule agent is available today to selected biotech and pharma partners. Teams interested in pilots can inquire via the company’s website. pauling.ai

About Pauling.AI

Pauling.AI builds AI agents that automate drug discovery. Headquartered in Boston, MA, the company’s platform compresses early discovery timelines by automating computational chemistry and in-silico candidate triage. Pauling.AI is led by Javier Tordable (ex-Google) and is a member of NVIDIA Inception.

###

Media Contact:

info@pauling.ai 

pauling.ai

newsroom: news.38digitalmarket.com

Source published by Submit Press Release >> Pauling.AI Announces Launch of Fully Automated Drug Discovery Agent for Small Molecules